drugset / Trial / NCT07406347
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
RandomizedParallel-groupTriple-blindPrevention
Summary
The main purpose of this study is to evaluate safety and reactogenicity of the investigational pneumococcal vaccine (called Pn-MAPS30plus). PCV20 will be used as a comparator for this study
Timeline
- Start
- 2027-01-25
- Primary completion
- 2028-10-18
- Completion
- 2028-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PCV20 | Vaccine | — | Intramuscular |
| Subject | Pn-MAPS30plus | Vaccine | — | Intramuscular |